Market capitalization | $1.99m |
Enterprise Value | $38.44m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 43.19 |
P/S ratio (TTM) P/S ratio | 2.24 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 4,855.56% |
Revenue (TTM) Revenue | $890.00k |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
1 Analyst has issued a forecast Progenity Inc:
1 Analyst has issued a forecast Progenity Inc:
Sep '24 |
+/-
%
|
||
Revenue | 0.89 0.89 |
4,350%
4,350%
|
|
Gross Profit | 0.45 0.45 |
178%
178%
|
|
EBITDA | -60 -60 |
10%
10%
|
EBIT (Operating Income) EBIT | -61 -61 |
10%
10%
|
Net Profit | -32 -32 |
74%
74%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Progenity, Inc., a biotechnology company, provides complex molecular and specialized testing services to physicians, clinicians, and their patients in the United States. It offers testing services for common hereditary disorders, cystic fibrosis, spinal muscular atrophy, fragile X syndrome, and Jewish genetic diseases; pan-ethnic carrier screening services; non-invasive prenatal, miscarriage, and pharmacogenetic testing services; and ovarian assessment reports for women. The company also provides pediatric testing services. Progenity, Inc. was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November, 2013. The company was incorporated in 2012 and is based in San Diego, California with a laboratory in Ann Arbor, Michigan. It has a bill payment location in Detroit, Michigan.
Head office | United States |
CEO | Adi Mohanty |
Employees | 58 |
Founded | 2010 |
Website | www.bioratherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.